Piper Jaffray to Host First Ever London Health Care Conference
June 19 2006 - 1:00AM
PR Newswire (US)
LONDON, June 19 /PRNewswire-FirstCall/ -- Piper Jaffray Ltd. is
pleased to announce it is holding its first London Health Care
Conference June 22-23 in the United Kingdom. The conference will
feature presentations by management teams in the biopharmaceutical
and medical technology industries from both Europe and the United
States. Presentations will last approximately 20 minutes. "We are
delighted to be hosting our first health care conference in the
UK," said David Wilson, chief executive officer of Piper Jaffray
Ltd. "The conference includes a very strong line-up of leading
biopharmaceutical and medical technology companies that will
provide clients updated insight on current and new trends in the
industry." Piper Jaffray will also be hosting its 18th annual U.S.
Health Care Conference November 29-December 1 in New York.
Companies scheduled to present and attend the London Health Care
Conference include: Acambis Plc, Actelion Ltd., Alizyme Plc,
Allergy Therapeutics Ltd., Alliance Pharma Plc, Amylin
Pharmaceuticals, Inc., Anadys Pharmaceuticals, Inc., Antisoma Plc,
Ardana Plc, Ark Therapeutics Group Plc, Arpida Ag, ArthroCare
Corporation, Asterand Plc, Axis-Shield Plc, Basilea Pharmaceutica
Ltd., Bespak Plc, BioAlliance Pharma, Biocompatibles International
Plc, BTG Plc, Celgene Corporation, CeNeS Pharmaceuticals Plc, Corin
Group Plc, Crucell NV, Cubist Pharmaceuticals Inc., CuraGen
Corporation, Evolutec Group Plc, Evotec AG, Exelixis, Inc., Exonhit
Therapeutics SA, Galapagos nv, Genetix Group Plc, Genmab A/S, GPC
Biotech AG, Gyrus Group Plc, Huntleigh Technology Plc, Immucor,
Inc., Inion Oy, Innogenetics NV, Innovata Plc, Integra LifeSciences
Holdings Corporation, Intercytex Group Plc, Jerini AG, Kyphon Inc.,
MannKind Corporation, Micromet, Inc., NeuroSearch A/S, NicOx SA,
Osmetech Plc, Oxford BioMedica Plc, Pharmexa A/S, Plethora
Solutions, ProStraken, Protherics Plc, Qiagen, SGX Pharmaceuticals,
Inc., Sinclair Pharmaceuticals, SkyePharma Plc, Smith & Nephew
plc, SpaceLabs Healthcare, Speedel Pharmaceuticals Inc., Tissue
Science Laboratories plc, TopoTarget A/S, Vectura Group Plc,
Vernalis Plc, Vertex Pharmaceuticals Inc., Vical Incorporated,
Vital Signs Inc., Wright Medical Group, Inc. Company and investor
participation in the Piper Jaffray London Health Care Conference is
by invitation only. Clients interested in attending should contact
their Piper Jaffray representative. Piper Jaffray Companies
(NYSE:PJC) is a focused securities firm dedicated to delivering
superior financial advice, investment products and transaction
execution within selected sectors of the financial services
marketplace. The company currently operates through two primary
revenue-generating segments: Capital Markets and Private Client
Services. The sale of the company's Private Client Services branch
network, announced April 11, 2006, currently is pending. The
company's Capital Markets business generates revenue through two
groups: Corporate and Institutional Services and Public Finance
Services. Through its chief operating subsidiary in the U.S., Piper
Jaffray & Co., the firm has served corporations, government and
non-profit entities, institutional investors and the financial
advisory needs of private individuals since 1895. With headquarters
in Minneapolis, Piper Jaffray currently has approximately 2,800
employees in 107 offices in 23 states across the country and in
London. The firm's UK operating subsidiary, Piper Jaffray Ltd., is
authorized and regulated by the Financial Services Authority and is
a member of the London Stock Exchange. For more information about
Piper Jaffray, visit us online at http://www.piperjaffray.com/ .
Since 1895. Member SIPC and NYSE. SOURCE Piper Jaffray Ltd.
CONTACT: Rob Litt of Piper Jaffray Ltd., +1-612-303-8266, Web site:
http://www.piperjaffray.com/
Copyright
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Oct 2023 to Oct 2024